MCID: CLR003
MIFTS: 56

Clear Cell Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Clear Cell Adenocarcinoma

MalaCards integrated aliases for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma 12 15
Mesonephroma 12 44 73
Water-Clear Cell Adenocarcinoma 12 73
Adenocarcinoma, Clear Cell 44 73
Mesonephroid Clear Cell Carcinoma 12
Water-Clear Cell Carcinoma 12
Adenocarcinoma Clear Cell 55
Mesonephroma, Malignant 12
Malignant Mesonephroma 12
Wolffian Duct Neoplasm 12
Mesonephric Tumor 73

Classifications:



Summaries for Clear Cell Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Clear Cell Adenocarcinoma, also known as mesonephroma, is related to urethra clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Developmental Biology and Endometrial cancer. The drugs Doxorubicin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, ovary and colon, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Wikipedia : 76 Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear... more...

Related Diseases for Clear Cell Adenocarcinoma

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
# Related Disease Score Top Affiliating Genes
1 urethra clear cell adenocarcinoma 33.9 AMACR KLK3 SMAD4
2 ovarian clear cell adenocarcinoma 33.3 ARID1A HNF1B SMAD3
3 urethral diverticulum 30.4 AMACR KLK3 KRT7
4 endodermal sinus tumor 30.1 KLK3 KRT7 MUC16
5 vulva adenocarcinoma 29.9 KRT20 KRT7
6 transitional cell carcinoma 29.6 KRT20 KRT7 TP53
7 clear cell adenofibroma 29.5 ARID1A KRT7
8 nephrogenic adenoma 29.2 AMACR KLK3 KRT7 PAX2
9 ovarian cancer 1 29.0 ARID1A HNF1B KRT7 TP53
10 renal cell carcinoma, nonpapillary 27.2 AMACR HNF1B KRT20 KRT7 PAX2 PTHLH
11 clear cell adenocarcinoma of the ovary 12.3
12 cervical clear cell adenocarcinoma 12.3
13 endometrial clear cell adenocarcinoma 12.3
14 fallopian tube clear cell adenocarcinoma 12.2
15 bladder clear cell adenocarcinoma 12.1
16 uterine ligament clear cell adenocarcinoma 12.1
17 ampulla of vater clear cell adenocarcinoma 12.1
18 bile duct clear cell adenocarcinoma 12.1
19 bladder tubulo-cystic clear cell adenocarcinoma 12.1
20 bladder papillary clear cell adenocarcinoma 12.1
21 bladder diffuse clear cell adenocarcinoma 12.0
22 diethylstilbestrol syndrome 11.3
23 wolffian duct adenoma 11.1
24 multilocular cystic renal neoplasm of low malignant potential 11.1
25 adenocarcinoma 11.0
26 submandibular gland cancer 10.8 KLK3 TP53
27 atrophy of prostate 10.8 KLK3 TP53
28 mutyh-associated polyposis 10.7 SMAD4 TP53
29 penile disease 10.6 SMAD2 SMAD3
30 malignant spiradenoma 10.5 KRT7 TP53
31 pleomorphic adenoma carcinoma 10.5 PTHLH TP53
32 oligomeganephronia 10.5 HNF1B PAX2
33 female reproductive endometrioid cancer 10.5 KRT7 TP53
34 seminal vesicle tumor 10.5 KLK3 KRT7
35 adenomatoid tumor 10.5 KRT7 MUC16
36 bladder carcinoma in situ 10.5 KRT7 TP53
37 rete testis adenocarcinoma 10.5 KLK3 KRT20
38 breast squamous cell carcinoma 10.5 PTHLH TP53
39 vaginitis 10.5
40 endometriosis 10.5
41 urinary tract obstruction 10.4 KLK3 SMAD2 SMAD3
42 nasal cavity adenocarcinoma 10.4 KRT7 TP53
43 spiradenoma 10.4 KRT7 TP53
44 bladder papillary transitional cell neoplasm 10.4 KRT20 TP53
45 urinary tract papillary transitional cell benign neoplasm 10.4 KRT20 TP53
46 nephrogenic systemic fibrosis 10.4 SMAD2 SMAD3 SMAD4
47 villous adenoma 10.4 KLK3 KRT20
48 esophagus adenocarcinoma 10.4 SMAD4 TP53
49 pancreas adenocarcinoma 10.4 MUC16 SMAD4 TP53
50 cystic basal cell carcinoma 10.4 KRT20 KRT7

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:



Diseases related to Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.02 SMAD4 PTHLH AMACR SMAD2 ARID1A SMAD3
2 endocrine/exocrine gland MP:0005379 10.01 SMAD4 PAX2 PTHLH TP53 SMAD2 ARID1A
3 embryo MP:0005380 9.98 SMAD4 PAX2 TP53 SMAD2 ARID1A SMAD3
4 craniofacial MP:0005382 9.93 SMAD4 PTHLH TP53 SMAD2 ARID1A SMAD3
5 liver/biliary system MP:0005370 9.8 SMAD4 AMACR SMAD2 SMAD3 HNF1B TP53
6 renal/urinary system MP:0005367 9.7 PAX2 PTHLH TP53 SMAD3 HNF1B KRT7
7 neoplasm MP:0002006 9.65 SMAD4 SMAD2 ARID1A SMAD3 TP53
8 reproductive system MP:0005389 9.5 PAX2 SMAD4 PTHLH SMAD2 ARID1A SMAD3
9 vision/eye MP:0005391 9.1 PAX2 PTHLH SMAD2 ARID1A SMAD3 TP53

Drugs & Therapeutics for Clear Cell Adenocarcinoma

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
4
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
7
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
8
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
11
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
12
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
13
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
14
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
15
Cediranib Investigational Phase 3,Phase 2 288383-20-0 9933475
16
Maleic acid Experimental Phase 3,Phase 2 110-16-7 444266
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
19 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
22 Antimetabolites Phase 3,Phase 2,Phase 1
23 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
24 Adjuvants, Immunologic Phase 3,Phase 1
25 Mitogens Phase 3,Phase 2,Phase 1
26 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
27 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
28 Immunoglobulin G Phase 3,Phase 2,Phase 1
29 Antibodies Phase 3,Phase 2,Phase 1
30 Immunoglobulins Phase 3,Phase 2,Phase 1
31 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
32 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 3,Phase 2,Phase 1
34 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
35 Antiviral Agents Phase 3,Phase 2,Phase 1
36 Antimitotic Agents Phase 3,Phase 2,Phase 1
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
38 topoisomerase I inhibitors Phase 2, Phase 3
39 Micronutrients Phase 3,Not Applicable
40 Trace Elements Phase 3,Not Applicable
41 Hypoglycemic Agents Phase 2, Phase 3
42 Poly(ADP-ribose) Polymerase Inhibitors Phase 3,Phase 2,Phase 1
43 Carotenoids Phase 3
44 taxane Phase 3,Not Applicable
45
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
46
Vinblastine Approved Phase 2 865-21-4 13342 241903
47
Sunitinib Approved, Investigational Phase 2,Not Applicable 341031-54-7, 557795-19-4 5329102
48
Dasatinib Approved, Investigational Phase 2,Phase 1 302962-49-8 3062316
49
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
50
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
6 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
7 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
8 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
9 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
10 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
11 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
12 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
13 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
14 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
15 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
16 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
17 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
18 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
19 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
20 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
21 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2 Sunitinib
22 Immunochemotherapy for Metastatic Renal Cell Carcinoma Unknown status NCT00226798 Phase 2 Capecitabine (Xeloda)
23 Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
24 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed NCT01914510 Phase 2 ENMD-2076
25 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
26 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
27 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
28 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
29 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
30 Sunitinib in Metastatic Renal Cancer Completed NCT01034878 Phase 2 Sunitinib
31 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
32 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
33 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
34 Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Completed NCT00002562 Phase 2 paclitaxel
35 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
36 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
37 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
38 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
39 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
40 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
41 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
42 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
43 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
44 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
45 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
46 Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Completed NCT00113373 Phase 2 lapatinib ditosylate
47 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
48 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
49 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
50 Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. Recruiting NCT03066427 Phase 2 Sunitinib

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Genetic Tests for Clear Cell Adenocarcinoma

Anatomical Context for Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Clear Cell Adenocarcinoma:

41
Cervix, Ovary, Colon, Kidney, Lung, Lymph Node, Prostate

Publications for Clear Cell Adenocarcinoma

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 423)
# Title Authors Year
1
Ovarian Clear Cell Adenofibroma of Low Malignant Potential Developing Into Clear Cell Adenocarcinoma. ( 29551085 )
2018
2
Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. ( 29979406 )
2018
3
Clear Cell Adenocarcinoma Arising from Endometriosis in the Groin: Wide Resection and Reconstruction with a Fascia Lata Tensor Muscle Skin Flap. ( 29805826 )
2018
4
Unusual Features of Clear Cell Adenocarcinoma of the Female Urethra: A Case Report and Literature Review. ( 29977425 )
2018
5
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. ( 29933751 )
2018
6
Clear cell adenocarcinoma of female urethra: A case report. ( 29888186 )
2018
7
Clear cell adenocarcinoma of the urethra with inguinal lymph node metastases: A rare case report and review of literature. ( 29516944 )
2018
8
Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. ( 29719188 )
2018
9
Cervical clear cell adenocarcinoma with an exceptionally low proliferation index: Report of a case. ( 29326971 )
2018
10
Clear Cell Adenocarcinoma of the Urethra in Women: Distinctive MRI Findings for Differentiation From Nonadenocarcinoma and Non-Clear Cell Adenocarcinoma of the Urethra. ( 28140610 )
2017
11
Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. ( 28689666 )
2017
12
Clear cell adenocarcinoma of the cervix in second generation young women who are without maternal exposure to diethylstilbestrol: A case report. ( 28275694 )
2017
13
Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. ( 29184869 )
2017
14
Clear cell adenocarcinoma of cervix in 1-year-old girl without in utero exposure to diethylstilbestrol: an uncommon tumour at an uncommon age and site. ( 28302659 )
2017
15
Clear Cell Adenocarcinoma of Female Urethra. ( 28892907 )
2017
16
The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )
2017
17
Clear Cell Adenocarcinoma of the Female Urethra, Mimicking Cystocele. ( 28280687 )
2017
18
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. ( 27660815 )
2016
19
A clear cell adenocarcinoma of the gallbladder with hepatoid differentiation: case report and review of literature. ( 27703378 )
2016
20
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. ( 27699033 )
2016
21
Clear Cell Adenocarcinoma of the Female Urethra: Four Case Presentations of a Clinical and Pathological Entity Requiring Radical Surgery. ( 26807736 )
2016
22
Clear Cell Adenocarcinoma of the Lung Mimicking Clear Cell Renal Cell Carcinoma. ( 29772138 )
2016
23
Clear cell adenocarcinoma of the cervix in a ten-year-old girl without prenatal diethylstilbestrol exposure. ( 27549741 )
2016
24
Clear cell adenocarcinoma arising from adenomyotic cyst: A case report and literature review. ( 26530432 )
2015
25
Combined benign Brenner tumor and clear cell adenocarcinoma of the ovary. ( 26150073 )
2015
26
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. ( 26397155 )
2015
27
Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. ( 26090245 )
2015
28
Successful radiotherapy for repeated recurrent uterine clear cell adenocarcinoma. ( 26310385 )
2015
29
High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra. ( 26207115 )
2015
30
Clear cell adenocarcinoma of the urethra: review of the literature. ( 25685552 )
2015
31
A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis. ( 25642923 )
2015
32
Late recurrence in a case of vaginal clear cell adenocarcinoma unrelated to transplacental diethylstilbestrol exposure. ( 26905123 )
2015
33
Clear Cell Adenocarcinoma Arising from Adenofibroma in a Patient with Endometriosis of the Ovary. ( 26498012 )
2015
34
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. ( 25658832 )
2015
35
Clear cell adenocarcinoma of the bladder with intravesical cervical invasion. ( 26109625 )
2015
36
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. ( 25398420 )
2014
37
Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. ( 25083560 )
2014
38
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. ( 26082939 )
2014
39
Primary non-clear-cell adenocarcinoma of the vagina in a diethylstilbestrol exposed woman. ( 24690973 )
2014
40
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. ( 24707459 )
2014
41
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. ( 25010038 )
2014
42
Therapy of a clear cell adenocarcinoma of unknown primary arising in the abdominal wall after cesarean section and after hysterectomy. ( 25301100 )
2014
43
A case of clear cell adenocarcinoma arising from endometriosis of the rectum treated by laparoscopic surgery. ( 25460452 )
2014
44
Clear cell adenocarcinoma present exclusively within endometrial polyp: report of two cases. ( 24817975 )
2014
45
Clear Cell Adenocarcinoma of the Urethra: 18F-FDG PET/CT Imaging. ( 25140553 )
2014
46
Primary clear cell adenocarcinoma of the peritoneum presents as Sister Mary Joseph's nodule: a case report and literature review. ( 25556287 )
2014
47
Primary Urethral Clear-Cell Adenocarcinoma: Comprehensive Analysis by Surgical Pathology, Cytopathology, and Next-Generation Sequencing. ( 24389164 )
2014
48
Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. ( 24815386 )
2014
49
Cervical clear cell adenocarcinoma infected with human papillomavirus type 18 in an adolescent. ( 23849091 )
2014
50
Clear Cell Adenocarcinoma of the Prostate: A Rare Oncologic Entity in a 42-Year-Old African American Man. ( 25217452 )
2014

Variations for Clear Cell Adenocarcinoma

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 218693 7 116312458 116438439 Amplification MET Clear cell adenocarcinoma
2 266962 Y 174481503 174538309 Duplication AZF Clear cell adenocarcinoma

Expression for Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Pathways for Clear Cell Adenocarcinoma

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 HNF1B KRT20 KRT7 SMAD2 SMAD3 SMAD4
2
Show member pathways
12.73 KLK3 SMAD2 SMAD3 SMAD4 TP53
3 12.69 KLK3 SMAD2 SMAD3 SMAD4 TP53
4
Show member pathways
12.61 ARID1A SMAD2 SMAD3 SMAD4 TP53
5
Show member pathways
12.45 SMAD2 SMAD3 SMAD4 TP53
6
Show member pathways
12.38 HNF1B SMAD2 SMAD3 SMAD4
7 12.32 SMAD2 SMAD3 SMAD4 TP53
8 12.24 SMAD2 SMAD3 SMAD4 TP53
9
Show member pathways
12.22 SMAD2 SMAD3 SMAD4 TP53
10
Show member pathways
12.14 HNF1B PTHLH SMAD2 SMAD3 SMAD4
11
Show member pathways
12.12 SMAD2 SMAD3 SMAD4
12 12.07 SMAD2 SMAD3 TP53
13 12.06 PAX2 SMAD2 SMAD3 SMAD4
14 12.05 SMAD2 SMAD3 SMAD4
15 12.05 SMAD2 SMAD4 TP53
16 12 SMAD2 SMAD3 SMAD4
17
Show member pathways
11.99 SMAD2 SMAD3 SMAD4
18 11.99 SMAD2 SMAD3 SMAD4
19 11.95 SMAD2 SMAD3 SMAD4 TP53
20 11.91 SMAD3 SMAD4 TP53
21 11.87 SMAD3 SMAD4 TP53
22 11.84 SMAD2 SMAD3 SMAD4 TP53
23 11.83 SMAD2 SMAD3 SMAD4
24 11.83 SMAD2 SMAD3 SMAD4 TP53
25 11.81 SMAD2 SMAD3 SMAD4
26
Show member pathways
11.8 SMAD2 SMAD3 SMAD4
27 11.78 KLK3 SMAD3 SMAD4
28 11.74 SMAD2 SMAD3 SMAD4
29 11.72 SMAD3 SMAD4 TP53
30
Show member pathways
11.69 SMAD2 SMAD3 SMAD4
31 11.69 SMAD2 SMAD3 SMAD4
32 11.64 SMAD2 SMAD3 SMAD4
33 11.64 SMAD2 SMAD3 SMAD4
34
Show member pathways
11.62 SMAD2 SMAD3 SMAD4
35 11.5 SMAD2 SMAD3 SMAD4
36 11.42 SMAD3 SMAD4 TP53
37 11.41 SMAD2 SMAD3 SMAD4
38
Show member pathways
11.39 SMAD2 SMAD3 SMAD4
39 11.32 SMAD2 SMAD3 TP53
40
Show member pathways
11.19 SMAD2 SMAD3 SMAD4
41 11.02 SMAD2 SMAD3 SMAD4
42 11 SMAD3 SMAD4
43 10.73 SMAD2 SMAD3 SMAD4
44 10.41 SMAD2 SMAD3 SMAD4
45 10.05 SMAD2 SMAD3 SMAD4

GO Terms for Clear Cell Adenocarcinoma

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 9.62 HNF1B SMAD2 SMAD3 SMAD4
2 nuclear chromatin GO:0000790 9.35 ARID1A SMAD2 SMAD3 SMAD4 TP53
3 activin responsive factor complex GO:0032444 9.26 SMAD2 SMAD4
4 heteromeric SMAD protein complex GO:0071144 9.16 SMAD2 SMAD3
5 SMAD protein complex GO:0071141 8.8 SMAD2 SMAD3 SMAD4

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.97 ARID1A HNF1B SMAD2 SMAD3 SMAD4 TP53
2 positive regulation of gene expression GO:0010628 9.94 HNF1B SMAD2 SMAD3 TP53
3 negative regulation of cell proliferation GO:0008285 9.92 PTHLH SMAD2 SMAD3 SMAD4 TP53
4 protein deubiquitination GO:0016579 9.89 SMAD2 SMAD3 SMAD4 TP53
5 negative regulation of cell growth GO:0030308 9.8 SMAD3 SMAD4 TP53
6 positive regulation of transcription, DNA-templated GO:0045893 9.8 ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4
7 anterior/posterior pattern specification GO:0009952 9.79 HNF1B SMAD2 SMAD4
8 transforming growth factor beta receptor signaling pathway GO:0007179 9.79 SMAD2 SMAD3 SMAD4
9 SMAD protein signal transduction GO:0060395 9.72 SMAD2 SMAD3 SMAD4
10 positive regulation of epithelial to mesenchymal transition GO:0010718 9.69 SMAD2 SMAD3 SMAD4
11 embryonic pattern specification GO:0009880 9.66 SMAD2 SMAD3
12 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.65 SMAD3 TP53
13 signal transduction involved in regulation of gene expression GO:0023019 9.65 SMAD2 SMAD3
14 osteoblast development GO:0002076 9.64 PTHLH SMAD3
15 activin receptor signaling pathway GO:0032924 9.63 SMAD2 SMAD3
16 secondary palate development GO:0062009 9.62 SMAD2 SMAD4
17 nodal signaling pathway GO:0038092 9.61 SMAD2 SMAD3
18 primary miRNA processing GO:0031053 9.6 SMAD2 SMAD3
19 pericardium development GO:0060039 9.58 SMAD2 SMAD3
20 embryonic foregut morphogenesis GO:0048617 9.58 SMAD2 SMAD3
21 developmental growth GO:0048589 9.58 SMAD2 SMAD3 SMAD4
22 pronephros development GO:0048793 9.56 HNF1B PAX2
23 regulation of transforming growth factor beta2 production GO:0032909 9.54 SMAD3 SMAD4
24 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.54 SMAD2 SMAD3 SMAD4
25 SMAD protein complex assembly GO:0007183 9.5 SMAD2 SMAD3 SMAD4
26 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.48 HNF1B PAX2
27 nephric duct formation GO:0072179 9.46 HNF1B PAX2
28 gastrulation GO:0007369 9.46 ARID1A SMAD2 SMAD3 SMAD4
29 paraxial mesoderm morphogenesis GO:0048340 9.43 SMAD2 SMAD3
30 endoderm development GO:0007492 9.26 HNF1B SMAD2 SMAD3 SMAD4
31 regulation of binding GO:0051098 8.8 SMAD2 SMAD3 SMAD4
32 transcription, DNA-templated GO:0006351 10.2 ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4
33 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 HNF1B PAX2 SMAD2 SMAD3 SMAD4 TP53

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.87 ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4
2 chromatin binding GO:0003682 9.84 SMAD2 SMAD3 SMAD4 TP53
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.81 SMAD2 SMAD3 SMAD4 TP53
4 transcription factor binding GO:0008134 9.78 PAX2 SMAD2 SMAD3 TP53
5 protein heterodimerization activity GO:0046982 9.77 HNF1B SMAD2 SMAD3 SMAD4 TP53
6 transcription factor activity, transcription factor binding GO:0000989 9.55 SMAD3 SMAD4
7 enhancer binding GO:0035326 9.49 SMAD2 SMAD3
8 co-SMAD binding GO:0070410 9.46 SMAD2 SMAD3
9 I-SMAD binding GO:0070411 9.43 SMAD2 SMAD4
10 primary miRNA binding GO:0070878 9.4 SMAD2 SMAD3
11 transcription regulatory region DNA binding GO:0044212 9.35 HNF1B PAX2 SMAD3 SMAD4 TP53
12 R-SMAD binding GO:0070412 9.33 SMAD2 SMAD3 SMAD4
13 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.26 SMAD2 SMAD3
14 proximal promoter sequence-specific DNA binding GO:0000987 8.92 HNF1B PAX2 SMAD3 SMAD4
15 DNA binding GO:0003677 10.07 ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4

Sources for Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....